Victoza(R) Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events

PR69788

BARCELONA, Spain, Aug. 28, 2017 /PRNewswire=KYODO JBN/ --

     Oral Presentation 3909

    A new analysis of the landmark LEADER trial shows that Victoza(R)

(liraglutide) reduced the risk of major cardiovascular (CV) events in people

with type 2 diabetes at high CV risk, irrespective of their history of having a

heart attack and/or stroke or not having any of these events, when compared to

placebo.[1] This post-hoc analysis was presented today at the European Society

of Cardiology (ESC) Annual Congress in Barcelona, Spain.

    Cardiovascular disease is the leading cause of morbidity and mortality in

people with diabetes.[2] Furthermore, studies have shown that adults with type

2 diabetes have up to a four times greater risk of heart attack and stroke.[3]

    "This new analysis expands our understanding of the benefits of Victoza(R)

in reducing cardiovascular risk in people with type 2 diabetes," said Professor

Neil Poulter, on behalf of the LEADER Trial Steering Committee and

Investigators. "These encouraging results are consistent with the

cardiovascular benefits of Victoza(R) observed in LEADER in both people with a

history of having a heart attack and/or stroke as well as people at high risk

without prior history of these types of cardiovascular events."

    Victoza(R) reduced the risk of major CV events (non-fatal heart attack,

non-fatal stroke and CV death) by 16% in people who had already experienced a

heart attack and/or stroke when the trial started. Similarly, a non-significant

11% risk reduction was achieved with Victoza(R) treatment in people who had not

experienced a prior heart attack and/or stroke.

    About Victoza(R)

    Victoza(R) (liraglutide) is a human glucagon-like peptide-1 (GLP-1)

analogue with an amino acid sequence 97% similar to endogenous human GLP-1.

Victoza(R) was approved in the EU in 2009 and is commercially available in more

than 95 countries, treating more than 1 million people with type 2 diabetes

globally.[4] In Europe, Victoza(R) is indicated for the treatment of adults

with insufficiently controlled type 2 diabetes together with diet and exercise,

as monotherapy when metformin is considered inappropriate due to intolerance or

contraindications and in addition to other medicinal products for the treatment

of type 2 diabetes.[5]

    About the LEADER trial

    LEADER was a multicentre, international, randomised, double-blind,

placebo-controlled trial investigating the long-term (3.5-5 years) effects of

Victoza(R) (liraglutide) compared to placebo, both in addition to standard of

care, in people with type 2 diabetes at high risk of major cardiovascular

events. Standard of care was comprised of lifestyle modifications,

glucose-lowering treatments and cardiovascular medications.[6]

    The landmark LEADER trial was initiated in September 2010 and randomised

9,340 people with type 2 diabetes from 32 countries. The primary endpoint was

the first occurrence of a composite cardiovascular outcome comprising

cardiovascular death, non-fatal heart attack or non-fatal stroke.[6]

    Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 41,400

people in 77 countries and markets its products in more than 165 countries. For

more information, visit novonordisk.com [https://www.novonordisk.com ],  

Facebook [http://www.facebook.com/novonordisk ], Twitter

[http://www.twitter.com/novonordisk ], LinkedIn

[http://www.linkedin.com/company/novo-nordisk ], YouTube

[http://www.Youtube.com/novonordisk ]  

    References

    1.    Poulter N, Bain SC, Buse J, et al. Risk of major cardiovascular

events in patients with type 2 diabetes with and without prior cardiovascular

events: results from the LEADER trial. Presentation at the European Society of

Cardiology. 2017.

2.    Diabetes Mellitus: A Major Risk Factor for Cardiovascular Disease.

Circulation; September 1999; 100(10):1132-1133.  

3.    Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, del Cañizo-Gómez

FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same

strength? World J Diabetes. 2014;5(4):444-470.   

4.    Internal Calculations based on IMS Midas Quantum data. April 2017.  

5.    EMA. Victoza(R) (liraglutide) Summary of Opinion (post authorisation).

Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/001026/WC500229898.pdf.

Last accessed: August 2017.

6.    Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and

cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;374:311-322.

     Further information:   

    Media:   

    Katrine Sperling     

    +45-4442-6718

    krsp@novonordisk.com  

    Asa Josefsson     

    +45-3079-7708   

    aajf@novonordisk.com

    Investors:

    Peter Hugreffe Ankersen

    +45-3075-9085

    phak@novonordisk.com   

    Hanna Ogren

    +45-3079-8519   

    haoe@novonordisk.com   

    Anders Mikkelsen  

    +45-3079-4461   

    armk@novonordisk.com    

    Christina Jensen

    +45-3079-3009

    cnje@novonordisk.com   

    Kasper Veje (US)

    +1-609-235-8567

    kpvj@novonordisk.com   

    SOURCE: Novo Nordisk